NO20021846L - Imidazolderivater som fosfodiesterase VII-inhibitorer - Google Patents

Imidazolderivater som fosfodiesterase VII-inhibitorer

Info

Publication number
NO20021846L
NO20021846L NO20021846A NO20021846A NO20021846L NO 20021846 L NO20021846 L NO 20021846L NO 20021846 A NO20021846 A NO 20021846A NO 20021846 A NO20021846 A NO 20021846A NO 20021846 L NO20021846 L NO 20021846L
Authority
NO
Norway
Prior art keywords
imidazole derivatives
phosphodiesterase vii
vii inhibitors
inhibitors
phosphodiesterase
Prior art date
Application number
NO20021846A
Other languages
English (en)
Other versions
NO20021846D0 (no
Inventor
Hans Michael Eggenweiler
Jonas Rochus
Michael Wolf
Michael Gassen
Oliver Poeschke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20021846D0 publication Critical patent/NO20021846D0/no
Publication of NO20021846L publication Critical patent/NO20021846L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
NO20021846A 1999-10-21 2002-04-19 Imidazolderivater som fosfodiesterase VII-inhibitorer NO20021846L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19950647A DE19950647A1 (de) 1999-10-21 1999-10-21 Imidazolderivate als Phosphodiesterase VII-Hemmer
PCT/EP2000/009926 WO2001029049A2 (de) 1999-10-21 2000-10-10 Imidazolderivate als phosphodiesterase vii-hemmer

Publications (2)

Publication Number Publication Date
NO20021846D0 NO20021846D0 (no) 2002-04-19
NO20021846L true NO20021846L (no) 2002-04-19

Family

ID=7926352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021846A NO20021846L (no) 1999-10-21 2002-04-19 Imidazolderivater som fosfodiesterase VII-inhibitorer

Country Status (22)

Country Link
EP (1) EP1222193B1 (no)
JP (1) JP2003512381A (no)
KR (1) KR20020060201A (no)
CN (1) CN1382146A (no)
AR (1) AR026198A1 (no)
AT (1) ATE247121T1 (no)
AU (1) AU780788B2 (no)
BR (1) BR0014922A (no)
CA (1) CA2388314C (no)
CZ (1) CZ293751B6 (no)
DE (2) DE19950647A1 (no)
DK (1) DK1222193T3 (no)
ES (1) ES2200957T3 (no)
HU (1) HUP0203139A3 (no)
MX (1) MXPA02003952A (no)
NO (1) NO20021846L (no)
PL (1) PL355020A1 (no)
PT (1) PT1222193E (no)
RU (1) RU2259199C2 (no)
SK (1) SK4922002A3 (no)
WO (1) WO2001029049A2 (no)
ZA (1) ZA200203995B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439784C (en) 2001-12-13 2010-11-02 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7 inhibiting action
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
MX2007000214A (es) 2004-07-01 2007-05-10 Asubio Pharma Co Ltd Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
MX2009010450A (es) 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
KR20220047894A (ko) 2010-11-08 2022-04-19 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305954A (en) * 1981-02-11 1981-12-15 E. I. Du Pont De Nemours And Company Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones
CA2346937A1 (en) * 1998-10-15 2000-04-27 Per O. G. Arkhammar Specific therapeutic interventions obtained by interference with redistribution and/or targeting
WO2000068230A1 (en) * 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors

Also Published As

Publication number Publication date
EP1222193A2 (de) 2002-07-17
ES2200957T3 (es) 2004-03-16
NO20021846D0 (no) 2002-04-19
DE19950647A1 (de) 2001-04-26
DE50003309D1 (de) 2003-09-18
PL355020A1 (en) 2004-03-22
RU2259199C2 (ru) 2005-08-27
CA2388314C (en) 2009-06-16
BR0014922A (pt) 2002-06-11
DK1222193T3 (da) 2003-12-01
SK4922002A3 (en) 2002-09-10
AU780788B2 (en) 2005-04-14
HUP0203139A2 (hu) 2003-01-28
PT1222193E (pt) 2003-12-31
MXPA02003952A (es) 2004-09-06
HUP0203139A3 (en) 2004-12-28
CA2388314A1 (en) 2001-04-26
CZ293751B6 (cs) 2004-07-14
CN1382146A (zh) 2002-11-27
KR20020060201A (ko) 2002-07-16
JP2003512381A (ja) 2003-04-02
ATE247121T1 (de) 2003-08-15
ZA200203995B (en) 2003-10-29
EP1222193B1 (de) 2003-08-13
WO2001029049A3 (de) 2001-11-01
AR026198A1 (es) 2003-01-29
WO2001029049A2 (de) 2001-04-26
CZ20021251A3 (cs) 2002-07-17
AU1135601A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
NO20021239L (no) Pteridinoner som kinase-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
IS6662A (is) Imídasól afleiður
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE360620T1 (de) Imidazolderivate
DK1185529T3 (da) Pyrazolbenzodiazepiner som CDK2-inhibitorer
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
ATE425147T1 (de) Imidazolderivate
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
DK1228073T3 (da) Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20014234D0 (no) Pyrazol-3-on-derivater som faktor-Xa-inhibitorer
ATE262517T1 (de) Thiopyranderivate as mmp-inhibitoren
ATE262528T1 (de) Substituierte purine-derivate als zell- adhäsionhemmer
EE200200389A (et) Imidasooli uued derivaadid
NO20020592D0 (no) Fluorenderivater som integrininhibitorer
ATE264308T1 (de) Aminoalkyl-3,4-dihydrochinolin-derivate als no synthase inhibitoren
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application